Close

Roth Capital Upgrades Syros Pharmaceuticals (SYRS) to Buy

November 5, 2018 7:31 AM EST Send to a Friend
Roth Capital analyst Matt Koranda upgraded Syros Pharmaceuticals (NASDAQ: SYRS) from Neutral to Buy with a price target of $12.00.The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login